Methylseleninic acid superactivates p53-senescence cancer progression barrier in prostate lesions of pten-knockout mouse

Cancer Prevention Research

Volumn 9, Issue 1, 2016, Pages 35-42

  Wang, Lei ^a   Guo, Xiaolan ^a   Wang, Ji ^a   Jiang, Cheng ^b   Bosland, Maarten C ^c   Lü, Junxuan ^b,d   Deng, Yibin ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

^d PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; BETA GALACTOSIDASE; CYCLIN DEPENDENT KINASE INHIBITOR 1; KI 67 ANTIGEN; METHYLSELENINIC ACID; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; SELENIUM DERIVATIVE; UNCLASSIFIED DRUG; METHYLSELENIC ACID; ORGANOSELENIUM DERIVATIVE; PTEN PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CANCER SIZE; CELL AGING; CELL PROLIFERATION; CHRONOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TARGETING; HISTOPATHOLOGY; INVASIVE CARCINOMA; LONG TERM CARE; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE EPITHELIUM CELL; PROSTATE WEIGHT; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SHORT COURSE THERAPY; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR INVASION; WILD TYPE; ANIMAL; CHEMISTRY; DISEASE COURSE; DISEASE MODEL; EPITHELIUM; GENETICS; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; METABOLISM; ORAL DRUG ADMINISTRATION; PROSTATE; PROSTATIC NEOPLASMS; RANDOMIZATION;

ADMINISTRATION, ORAL; ANIMALS; CELL AGING; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EPITHELIUM; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, KNOCKOUT; ORGANOSELENIUM COMPOUNDS; PROSTATE; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84955291843     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-15-0236     Document Type: Article

References (28)

1. Clark LC, Combs GF Jr., Turnbull BW, Slate EH, Chalker DK, Chow J, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996;276:1957-63.
2. Algotar AM, Stratton MS, Ahmann FR, Ranger-Moore J, Nagle RB, Thompson PA, et al. Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer. Prostate. 2013; 73:328-35.
3. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009;301:39-51.
4. Marshall JR, Tangen CM, Sakr WA, Wood DP Jr., Berry DL, Klein EA, et al. Phase III trial of selenium to prevent prostate cancer inmenwith high-grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prev Res (Phila) 2011;4:1761-9.
5. El-Bayoumy K. The negative results of the SELECT study do not necessarily discredit the selenium-cancer prevention hypothesis. Nutr Cancer 2009;61:285-6.
6. Hatfield DL, Gladyshev VN. The Outcome of Selenium and Vitamin E Cancer Prevention Trial (SELECT) reveals the need for better understanding of selenium biology. Mol Intervent 2009;9:18-21.
7. Christensen MJ. Selenium and prostate cancer prevention: what next-if anything? Cancer Prev Res 2014;7:781-5.
8. Lu J, Jiang C, Zhang J. Cancer prevention with selenium: costly lessons and difficult but bright future prospects. In: Kong A-NT, editor. Inflammation, oxidative stress and cancer. CRC Press Taylor: Francis; 2014. p. 477-94.
9. Ozten N, Horton L, Lasano S, Bosland MC. Selenomethionine and alphatocopherol do not inhibit prostate carcinogenesis in the testosterone plus estradiol-treated NBL rat model. Cancer Prev Res 2010;3:371-80.
10. McCormick DL, Rao KV, Johnson WD, Bosland MC, Lubet RA, Steele VE. Null activity of selenium and vitamin E as cancer chemopreventive agents in the rat prostate. Cancer Prev Res 2010;3:381-92.
11. Lu J, Jiang C. Selenium and cancer chemoprevention: hypotheses integrating the actions of selenoproteins and selenium metabolites in epithelial and non-epithelial target cells. Antioxid Redox Signal 2005;7:1715-27.
12. Wang L, Bonorden MJ, Li GX, Lee HJ,HuH, Zhang Y, et al. Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit. Cancer Prev Res 2009;2:484-95.
13. Li GX, Lee HJ, Wang Z, Hu H, Liao JD, Watts JC, et al. Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite. Carcinogenesis 2008;29:1005-12.
14. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012;13:283-96.
15. Wang S, Gao J, LeiQ, Rozengurt N, Pritchard C, Jiao J, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003;4:209-21.
16. Alimonti A, Nardella C, Chen Z, Clohessy JG, Carracedo A, Trotman LC, et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest 2010;120:681-93.
17. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005;436:725-30.
18. Mills IG. Maintaining and reprogramming genomic androgen receptor activity in prostate cancer. Nat Rev Cancer 2014;14:187-98.
19. Jia S, Gao X, Lee SH, Maira SM, Wu X, Stack EC, et al. Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discov 2013;3:44-51.
20. Cho SD, Jiang C, Malewicz B, Dong Y, Young CY, Kang KS, et al. Methyl selenium metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription. Mol Cancer Ther 2004;3:605-11.
21. Dong Y, Lee SO, Zhang H, Marshall J, Gao AC, Ip C. Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res 2004;64:19-22.
22. Jiang C, Wang Z, Ganther H, Lu J. Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. Mol Cancer Ther 2002;1:1059-66.
23. Wang Z, JiangC,Ganther H, Lu J. Antimitogenic and proapoptotic activities of methylseleninic acid in vascular endothelial cells and associated effects on PI3K-AKT, ERK, JNK and p38 MAPK signaling. Cancer Res 2001;61: 7171-8.
24. Wu M, Wu RT, Wang TT, Cheng WH. Role for p53 in selenium-induced senescence. J Agric Food Chem 2011;59:11882-7.
25. WuM, Kang MM, Schoene NW, Cheng WH. Selenium compounds activate early barriers of tumorigenesis. J Biol Chem 2010;285:12055-62.
26. Wang L, Xiong H, Wu F, Zhang Y, Wang J, Zhao L, et al. Hexokinase 2-mediated Warburg effect is required for PTEN-and p53-deficiency-driven prostate cancer growth. Cell Rep 2014;8:1461-74.
27. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the bar harbor meeting of the mouse models of human cancer consortium prostate pathology committee. Cancer Res 2004;64:2270-305.
28. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011;19:575-86.